ReviewCells2020
New and Emerging Systemic Therapeutic Options for Advanced Cholangiocarcinoma.
Review in Cells, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed.
- Cholangiocarcinoma:Unveiling the cold tumor microenvironment and strategies for immune rejuvenation.Oncogene · 2026Review
- High incidence of intrahepatic cholangiocarcinoma in end-stage renal disease patients in Taiwan: analysis of a nationwide database with molecular insight of aristolochic acid exposure.Virchows Archiv : an international journal of pathology · 2026Article
- The impact of lipid metabolism remodeling in the tumor microenvironment on angiogenesis.Discover oncology · 2026Review
- HCG18 Promotes Cell Proliferation and Stemness in Cholangiocarcinoma via the miR-194-5p/KRT18/MAPK Signaling.Biochemical genetics · 2025Article
- Safety profiles of the new target therapies-pemigatinib, futibatinib, and ivosidenib-for the treatment of cholangiocarcinoma: a systematic review.Therapeutic advances in drug safety · 2025Review
- Advances in targeted therapy of cholangiocarcinoma.Annals of medicine · 2024Review
- Octamer-binding transcription factor 4-positive circulating tumor cell predicts worse treatment response and survival in advanced cholangiocarcinoma patients who receive immune checkpoint inhibitors treatment.World journal of surgical oncology · 2024Article
- Preoperative predictors for non-resectability in perihilar cholangiocarcinoma.World journal of surgical oncology · 2024Article
- Any role for transarterial radioembolization in unresectable intrahepatic cholangiocarcinoma in the era of advanced systemic therapies?World journal of hepatology · 2023Review
- Regulation of glucose and glutamine metabolism to overcome cisplatin resistance in intrahepatic cholangiocarcinoma.BMB reports · 2023Article
- Infectious Agents Induce Wnt/β-Catenin Pathway Deregulation in Primary Liver Cancers.Microorganisms · 2023Review
- Immunotherapy as adjuvant therapy for a patient with adenosquamous carcinoma of the intrahepatic bile duct: A case report and literature review.Liver research (Beijing, China) · 2023Article
- Artificial Intelligence-Based Opportunities in Liver Pathology-A Systematic Review.Diagnostics (Basel, Switzerland) · 2023Review
- Endoscopic biliary treatment of unresectable cholangiocarcinoma: A meta-analysis of survival outcomes and systematic review.World journal of gastrointestinal endoscopy · 2023Article
- Bone Metastases from Intrahepatic Cholangiocarcinoma Confer Worse Prognosis.Current oncology (Toronto, Ont.) · 2023Article
- Risk Assessment and Cholangiocarcinoma: Diagnostic Management and Artificial Intelligence.Biology · 2023Review
- Identification of immune related gene signature for predicting prognosis of cholangiocarcinoma patients.Frontiers in immunology · 2023Article
- Neoadjuvant therapy use and association with postoperative outcomes and overall survival in patients with extrahepatic cholangiocarcinoma.Journal of surgical oncology · 2023Article
- Immune microenvironment of cholangiocarcinoma: Biological concepts and treatment strategies.Frontiers in immunology · 2023Review
- Laparoscopic versus open hepatectomy for intrahepatic cholangiocarcinoma in patients aged 60 and older: a retrospective cohort study.World journal of surgical oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cholangiocarcinoma (CCA) represents a disease entity that comprises a heterogeneous group of biliary malignant neoplasms, with variable clinical presentation and severity. It may be classified according to its anatomical location and distinguished in intrahepatic (iCCA), perihilar (pCCA), or distal (dCCA), each subtype implying distinct epidemiology, biology, prognosis, and strategy for clinical management. Its incidence has increased globally over the past few decades, and its mortality rate remains high due to both its biological aggressiveness and resistance to medical therapy. Surgery is the only potentially curative treatment and is the standard approach for resectable CCA; however, more than half of the patients have locally advanced or metastatic disease at presentation. For patients with unresectable CCA, the available systemic therapies are of limited effectiveness. However, the advances of the comprehension of the complex molecular landscape of CCA and its tumor microenvironment could provide new keys to better understand the pathogenesis, the mechanisms of resistance and ultimately to identify promising new therapeutic targets. Recently, clinical trials targeting isocitrate dehydrogenase (IDH)-1 mutations and fibroblast growth factor receptor (FGFR)-2 fusions, as well as immunotherapy showed promising results. All these new and emerging therapeutic options are herein discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.